PDRN 81 Human Type I Collagen
200 150 100 50 0
Control RJMPDRN REC Figure 4: Type I and type III collagen generation
Recombinant humanized elastin: addressing the mechanical dimension of ageing The recombinant humanized elastin platform we review here addresses a more structural aspect of skin ageing. Elastin is essential to the formation of elastic fibres, which allow skin to stretch and recover while maintaining tissue integrity over repeated mechanical challenge.4,5 When elastin becomes depleted or
disorganised, the result is not only wrinkling but also sagging, slower recoil and reduced resistance to deformation. Conventional elastin actives have struggled to overcome this because elastin function depends heavily on conformation and supramolecular behaviour.6 Our recombinant humanized elastin is intended
to address the classic barriers that have historically limited the use of elastin: lack of secondary structure, poor water solubility, low expression yield, purification difficulty, endotoxin burden and poor transdermal delivery. The resulting material is described as a recombinant humanized elastin with 100% human-derived functional sequence identity and a biomimetic β-spiral secondary structure intended to reproduce the spring-like behaviour associated with native elastin. This structural claim is central. A primary-sequence elastin mimic is not necessarily enough; functional performance depends heavily on conformation and supramolecular behaviour. According to our technical dossier, the
ingredient is produced through an integrated platform including rational sequence design, secondary-structure folding control, soluble high-expression fermentation, specific enzymatic purification, endotoxin removal, transdermal delivery engineering and signalling-network integration. The reported final material reaches 98% purity, with an endotoxin level of 0.01 EU/ mL, well below the 0.5 EU/mL industry standard. For cosmetic developers, such parameters matter because safety perception and stability are often decisive when introducing biologically sophisticated proteins into leave-on care. Delivery has historically been a major objection
to topical elastin concepts. To address this, we pair our recombinant humanized elastin with an ADI multi-dimensional transdermal system. In our delivery evaluation, fluorescence imaging after
www.personalcaremagazine.com Skin Elasticity
0.800 0.700 0.600 0.500 0.400 0.300 0.200 0.100 0.000
0.642 ** 0.538 0.700 **
Skin Firmness 0.6343
7.000 6.000 5.000 4.000 3.000 2.000 1.000 0.00
Baseline value Figure 5: Skin elasticity
Wrinkle Count 15
20 18 16 14 12 10 8 6 4 2 0
Baseline value Figure 7: Wrinkle count
Wrinkle Area 56.82
70.00 60.00 50.00 40.00 30.00 20.00 10.00 0.00
Baseline value Figure 9: Wrinkle area
a single application showed signal in both the epidermis and dermis within one hour, supporting rapid skin penetration. Complementary in vivo Raman spectroscopy further showed a clear time-dependent increase
** 9 ** 8 14d 28d Baseline value Figure 6: Skin firmness
Wrinkle Length 47.90
60.00 50.00 40.00 30.00 20.00 10.00 0.00
14d 28d Baseline value Figure 8: Wrinkle length 52.86 ** 52.59 **
in skin permeability, rising from baseline to 5.62% at 0.5 h, 7.95% at 1 h, 10.62% at 2 h and 17.95% at 4 h, equivalent to a 7.5-fold increase versus 0 h. While proprietary delivery data should always be interpreted in the context of the exact test model, these findings are highly relevant to formulators: elastin is only meaningful as an active if it can reach the skin layers where elasticity is functionally determined. We have also observed notable formulation
14d 28d
robustness. Our dossier states that recombinant humanized elastin maintained activity without detectable degradation across temperatures from -20 °C to 60 °C and across pH 2-9 for as long as 189 days, while also showing compatibility in creams, serums and hydrogel-style applications. This is not a trivial advantage. Many high-value biomolecules fail not because they lack activity, but because they are too unstable for real-world formulation, manufacturing and shelf-life conditions.
September 2026 PERSONAL CARE MAGAZINE PDRN (Salmon) Human Type III Collagen
5000 4000 3000 2000 1000 0
Control RJMPDRN® REC PDRN (Salmon)
5.508 **
5.085 **
14d
28d
44.00 **
42.42 **
14d
28d
ng/mL
Wrinkle Area (mm2
) Wrinkle Count
R2 Value for Characterizing Skin Elasticity
ng/mL
Wrinkle Length (mm)
F4 Value for Characterizing Skin Firmness
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
